Evidence map›Paper›PMID 18647414›Full record

ArticleBMC immunology2008

Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.

Rogério S Rosada, Lucimara Gaziola de la Torre, Fabiani G Frantz, Ana P F Trombone, Carlos R Zárate-Bladés, Denise M Fonseca, Patrícia R M Souza, Izaíra T Brandão, Ana P Masson, Edson G Soares and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 104 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Research Progress on Liposome Pulmonary Delivery ofJournal of aerosol medicine and pulmonary drug delivery · 2024
    Review
  5. Review
  6. Review
  7. Nanotechnology of inhalable vaccines for enhancing mucosal immunity.Drug delivery and translational research · 2024
    Review
  8. Review
  9. Review
  10. Recent Patents on Nasal Vaccines Containing Nanoadjuvants.Recent advances in drug delivery and formulation · 2022
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Recombinant InvasiveFrontiers in microbiology · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Rogério S RosadaNúcleo de Pesquisas em Tuberculose, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.rosada@cpt.fmrp.usp.br
Lucimara Gaziola de la Torre
Fabiani G Frantz
Ana P F Trombone
Carlos R Zárate-Bladés
Denise M Fonseca
Patrícia R M Souza
Izaíra T Brandão
Ana P Masson
Edson G Soares
Simone G Ramos
Lúcia H Faccioli
Célio L Silva
Maria H A Santana
Arlete A M Coelho-Castelo
Universidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade de Ribeirão Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.

resultsWe developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 microg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-gamma and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 microg).

conclusionOur objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

Indexed as

Mycobacterium tuberculosisAdministration, IntranasalAnimalsBacterial ProteinsChaperonin 60ChaperoninsFemaleImmunity, ActiveImmunization, SecondaryLiposomesLymphocyte ActivationMiceMice, Inbred BALB CTh1 CellsTuberculosis, PulmonaryTuberculosis VaccinesBacterial ProteinsChaperonin 60Chaperoninsheat-shock protein 65, MycobacteriumLiposomesTuberculosis VaccinesVaccines, DNA

Identifiers

PMID18647414
PMCPMC2500095
OpenAlexW2099366654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.